Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BCRX - traded for flat, the wrong way. I took the profit in my call to ride a free put that will expire worthless unless BCRX implodes by Friday of next week.
Not going to chase now but if I still held a long position, I would be inclined to hold longer for this event:
Coronavirus Antiviral Program – Galidesivir (BCX4430)
Part 1 of a clinical trial of galidesivir in COVID-19 patients in Brazil has completed enrollment and the company expects to report results in the fourth quarter.
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14481537&RcvdDate=11/5/2020&CoName=BIOCRYST%20PHARMACEUTICALS%20INC&FormType=8-K&View=html
For biotechs: https://www.biopharmcatalyst.com/ offers a free daily newsletter which I try to read daily.
ARC 1.29 - joined you here with a first position. Looks very solid with recent exciting news...now if the chaotic-herd will just grab-a-holt
Did anyone watch the videolink (I know it's a long one)? Allison Patteson pops the champagne bottles at the 24:40 minute-mark for her initial success in the lab with pritumumab!
Nice. The tax-loss-selling might ease up a bit, ya think?
NBIO .05 - On December 7, 2020, the Company received a letter from the Federal Drug Administration (FDA) releasing the partial hold on the Company’s antibody Pritumumab. The release clears the Company to begin phase 1 clinical trials with its drug substance product.
Based on the approval by the FDA, the Company anticipates clinical trials to begin the first week in January, 2021.
https://ih.advfn.com/stock-market/USOTC/nascent-biotech-qb-NBIO/stock-news/83866997/current-report-filing-8-k
...so let's finds the next RSCF, see my next post?
GHIV 10.83 - joined you in writing some covered calls while premiums are flipping around in the ozone...
with my dropping of old cable-box-channels-tv and moving to all streaming-tv, I just switched back to Frontier Fios with brand new modem, better pricing and a move up to 500 Mbps.
Very happy so far...
SNFCA 8.86 - still well below a 5 P/E? Possibly it's wade buying??...ceasing being distracted by 'tripe-etf-scams' and focusing back on the bread-n-butter picks of this thread??
and still well below a 5 P/E?
AATV .43 - December 8, 2020...today announces...record revenue in December...
Reading between the lines...
SNFCA 8.12 - Amendment to Stock Repurchase Plan
On December 4, 2020, the Board of Directors of Security National Financial Corporation (the “Company”) approved an amendment to the Company’s Stock Repurchase Plan which authorized the repurchase of additional shares of the Company’s Class A Common Stock in the open market. This amendment in the form of an additional share repurchase authorization would increase the number of authorized shares that may be repurchased in the open market by another 700,000 shares of the Company’s Class A Common Stock. It should be noted that 234,323 of the original 300,000 shares of the Company’s Class A Common Stock that the Board authorized on September 7, 2018 have been repurchased in the open market.
https://ih.advfn.com/stock-market/NASDAQ/security-national-financ-SNFCA/stock-news/83847395/current-report-filing-8-k
SNFCA 8.12 - Amendment to Stock Repurchase Plan
On December 4, 2020, the Board of Directors of Security National Financial Corporation (the “Company”) approved an amendment to the Company’s Stock Repurchase Plan which authorized the repurchase of additional shares of the Company’s Class A Common Stock in the open market. This amendment in the form of an additional share repurchase authorization would increase the number of authorized shares that may be repurchased in the open market by another 700,000 shares of the Company’s Class A Common Stock. It should be noted that 234,323 of the original 300,000 shares of the Company’s Class A Common Stock that the Board authorized on September 7, 2018 have been repurchased in the open market.
https://ih.advfn.com/stock-market/NASDAQ/security-national-financ-SNFCA/stock-news/83847395/current-report-filing-8-k
I've read many of your old posts so I have zero reason to doubt that you got burned by these guys in some form of promiscuous stock game but my original question remains:
"Are the numbers all jibberish or did management actually figure out, over a period of several years, that 'legitimate trumps promiscuous' ALL DAY LONG?"
Stick around, N.A.T., and help us in answering this ever evolving question...
AATV .428 - December 2, 2020...The previously announced new installations of the Company's network and ad insertion equipment, magnified by the increased ad frequency due to unprecedented intense election ad campaigns nationwide, resulted in the Company generating the most revenue for any October and November in the Company's history...
...The Company's financial successes of 2020 has created a solid basis for the acceleration of its numerous new technology projects, which the Company expects to announce and launch soon. The Company anticipates that these projects and developments will allow the Company to continue its successful performance into the years beyond this historic election cycle.
https://www.otcmarkets.com/stock/AATV/news/Adaptive-Ad-Systems-Reports-Two-More-Record-Months-for-October--November-2020?id=282216
Are you suggesting that management is just spouting alot of jibberish here in an attempt to run a stock-dilution-scam?
AATV .428 - December 2, 2020...The previously announced new installations of the Company's network and ad insertion equipment, magnified by the increased ad frequency due to unprecedented intense election ad campaigns nationwide, resulted in the Company generating the most revenue for any October and November in the Company's history...
...The Company's financial successes of 2020 has created a solid basis for the acceleration of its numerous new technology projects, which the Company expects to announce and launch soon. The Company anticipates that these projects and developments will allow the Company to continue its successful performance into the years beyond this historic election cycle.
https://www.otcmarkets.com/stock/AATV/news/Adaptive-Ad-Systems-Reports-Two-More-Record-Months-for-October--November-2020?id=282216
I wish all of the stocks I own employed management team's this giddy in shouting success...fluffy or not!
NBIO .05 - Nov 20, 2020 - BioInspired Research: How does COVID-19 work and how can we stop it?
Nov 20, 2020 - BioInspired Research: How does COVID-19 work and how can we stop it?
AYSI 1.35 - why does otcmarkets.com have a warning...
Warning! This company has posted limited financial disclosure through the OTC Disclosure & News Service or is late in their filing obligations with the SEC.
https://www.otcmarkets.com/stock/AYSI/quote
Seems unwarranted for AYSI, but nonetheless an immediate turnoff to ANY potential new investor?
SNFCA 8.18 - ever so slightly showing some anticipated strength while the chart looks ready to burst...
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=snfca&insttype=&freq=1&show=&time=9
...and why not, trading at an approximate 3 P/E?
BLCM vs SYBX...if either pps were to get chopped in half?
I have no interest in BLCM.
I'd be tripling and quadrupling my current double-down position in SYBX.
https://investorshub.advfn.com/boards/board.aspx?board_id=38177
jmo
A weekend homework assignment w/bonuses for reading all associated links...
https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/?utm_campaign=+45058472&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=
BLCM 3.08 - I'm showing a negative BV of (48M) and of greater concern:
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 23, 2020, Bellicum Pharmaceuticals, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for the last 30 consecutive business days preceding the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) has been below the minimum of $35,000,000 required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”).
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14532706&RcvdDate=11/27/2020&CoName=BELLICUM%20PHARMACEUTICALS,%20INC&FormType=8-K&View=html
Looks like an inevitable secondary (at any pps) to avoid bankrupcy?
IMO the expectations shift from a 'fight' into a 'surrender' from either one or both?
but NO WAY they can continue remaining silent re: "the 069 patent" forever...
From the 10-Q, 11/5/20 - On July 23, 2020, the United States Patent and Trademark Office before the Patent Trial and Appeal Board ("PTAB") announced their decision in Moderna Therapeutics, Inc.'s challenge of the validity of U.S. Patent 8,058,069 ("the '069 Patent"). In this decision, the PTAB determined no challenged claims were unpatentable. While Arbutus is the patent holder, this patent has been licensed to Genevant. The '069 Patent was included in the license agreement between Genevant and Arbutus.
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14483120&RcvdDate=11/5/2020&CoName=ARBUTUS%20BIOPHARMA%20CORP&FormType=10-Q&View=html
The continued silence from both Arbutus & Moderna re: "the 069 patent" is deafening...
BCRX 5.14 —ORLADEYO™ (berotralstat) PDUFA date December 3, 2020—
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14481537&RcvdDate=11/5/2020&CoName=BIOCRYST%20PHARMACEUTICALS%20INC&FormType=8-K&View=html
I've slowly taken both a put&call position in anticipation of an overblown spike in either direction...less than 1% of my poke trying to implement a new strategy with focus on PDUFA's
In a normal market, the SPWH's should be trading much higher imo but it ain't a normal market as the most sickly of stocks continue flying to the moon sucking the wind from the SPWH's sails?
Half one's poke is a bit much to invest in super-high-risk stocks, yes? If you had invested say 5% of your poke...would you have been less afraid to hold and would you have been happy with the result?
For me, not about what I make in each trade, it's about what I LEARN...there'll always be another RSCF.
See NBIO...trading at a less than $5M cap
SPWH 14.20 - I've already shorted against my long-calls position for a flat trade and as it was an intended quick-trade on the earnings event. I was not impressed with the guidance:
Fourth quarter and fiscal year 2020 outlook:
For the fourth quarter of fiscal year 2020, net sales are expected to be in the range of $356 million to $386 million based on same store sales growth in the range of 32% to 42% compared to the corresponding period of fiscal year 2019. Adjusted EBITDA is expected to be in the range of $31.0 million to $35.0 million with diluted earnings per share of $0.39 to $0.45 on a weighted average of approximately 44.5 million estimated common shares outstanding.
SNFCA seems a way better place to camp some money right now and BGFV is so close to falling back to $7's which would make it a way better buy than SPWH, if it's not already.
SPWH 13.90 - reports afterclose today. yahoofinance has a rev/eps estimate of 328M/.47.
https://finance.yahoo.com/quote/SPWH/analysis?p=SPWH
I went long with a few $10 calls expecting they could crush that ".47 eps" number from watching others in the sportinggoods sector. Any other wags?
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
GOVX - I've kinda revised my outlook on "scams" to more of a "just-how-scammy-is-it" when factoring what to buy or sell.
And it would be hard to find a scammier longterm chart than GOVX?
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=govx&insttype=&freq=2&show=&time=20
Thanks but easy picks when the entire vaccine sector remains on fire. One would think with the successes of Moderna and Pfizer that all the second-tier vaccine plays would tank but quite the opposite...so far...
ABUS 4.56 - solid-sideplay off of MRNA and currently offering extreme covered call premiums.
SYBX - On June 11, 2019, Synlogic, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) with Ginkgo Bioworks, Inc. (“ Ginkgo ”), providing for the issuance and sale by the Company to Ginkgo of an aggregate of (i) 6,340,771 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price per Share of $9.00, and (ii) pre-funded warrants to purchase an aggregate of 2,548,117 shares of Common Stock (the “ Pre-Funded Warrants ”) at an exercise price of $9.00 per Share (the “ Offering ”), with $8.99 of such exercise price paid at the closing of the Offering. The gross proceeds to the Company will be approximately $80 million. The closing of the Offering took place on June 11, 2019.
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13487245&RcvdDate=6/12/2019&CoName=SYNLOGIC,%20INC.&FormType=8-K&View=html
SYBX - On June 11, 2019, Synlogic, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) with Ginkgo Bioworks, Inc. (“ Ginkgo ”), providing for the issuance and sale by the Company to Ginkgo of an aggregate of (i) 6,340,771 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price per Share of $9.00, and (ii) pre-funded warrants to purchase an aggregate of 2,548,117 shares of Common Stock (the “ Pre-Funded Warrants ”) at an exercise price of $9.00 per Share (the “ Offering ”), with $8.99 of such exercise price paid at the closing of the Offering. The gross proceeds to the Company will be approximately $80 million. The closing of the Offering took place on June 11, 2019.
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13487245&RcvdDate=6/12/2019&CoName=SYNLOGIC,%20INC.&FormType=8-K&View=html